阿托伐他汀对急性冠脉综合征患者高敏C反应蛋白及同型半胱氨酸水平的影响  

Effects of atorvastatin on the serum high sensitivity C-reactive protein and homocysteine in patients with acute coronary syndrome

作　　者：刘洋[1] 邱雪梅[2] 金海英[2] 马春梅[2] 

机构地区：[1]中国人民武装警察部队总医院药剂科,北京100039 [2]中国人民武装警察部队总医院心内科,北京100039

出　　处：《中国急救复苏与灾害医学杂志》2010年第7期620-621,共2页China Journal of Emergency Resuscitation and Disaster Medicine

摘　　要：目的探讨阿托伐他汀干预对急性冠脉综合征（ACS）患者血浆高敏C反应蛋白（Hs—CRP）和同型半胱氨酸（Hcy）水平的影响。方法78例ACS患者随机均分为常规对照组和阿托伐他汀治疗组[除常规治疗外每晚8时给予阿托伐他汀1片（20mg）]。治疗前及治疗后4周取外周血，测定血浆Hs—CRP和Hcy的浓度。结果阿托伐他汀治疗组与常规对照组相比在治疗前Hs—CRP及Hcy水平无明显差异。与治疗前相比，阿托伐他汀治疗组治疗4周后血浆Hs—CRP及Hcy水平均显著低于治疗前（均P〈0．01），而常规对照组Hs—CRP和Hcy水平在治疗前后无明显变化。结论阿托伐他汀能够降低血浆Hs—CRP和Hcy水平，在ACS的治疗中具有重要作用。Objective To investigate the effects of atorvastatin treatment on levels of serum high sensitivity C- reactive protein （Hs-CRP） and homocysteine （Hcy） in patients with acute coronary syndrome （ACS）. Methods 78 patients with ACS Were randomly divided into 2 equal groups： atorvastatin group taking atorvastatin orally 10 mg once every evening for 4 weeks in addition to conventional treatment, and control group treated with conventional medicine. Before and 4 weeks after the treatment peripheral blood samples were collected to detect the serum Hs-CRP and Hcy. Results There were not significant differences in the levels of serum Hs-CRP and Hcy between these 2 groups before treatment. Both the serum levels of Hs-CRP and Hcy of the atorvastatin treatment group decreased significantly 4 weeks after the treatment compared with those before treatment （P 〈 0. 01）. However, both the serum levels of Hs-CRP and Hcy of the atorvastatin group did not show significant differences 4 weeks after the beginning of conventional treatment. Conclusion Atorvastatin decreases the serum Hs-CRP and I-Icy levels, and is important in the treatment of ACS.

关 键 词：急性冠脉综合征 高敏C反应蛋白 同型半胱氨酸 阿托伐他汀 

分 类 号：R541.4[医药卫生—心血管疾病] R972.26[医药卫生—内科学]